522 - Efficacy and safety of abrocitinib in combination with…
Emerging
0
Citations0
Refs2024
Year
Search Works
Work Details
- DOI 10.1093/bjd/ljad498.027
- OpenAlex ID W4391609663
- Type Article
- Language EN
- Published 01 Feb 2024
- Volume 190 (Supplement_2)
- Pages ii23–ii24
- Source British Journal of Dermatology
- Publisher Oxford University Press
- Countries 2
- Institutions 8
- Added 08 Feb 2024
- Updated 27 Oct 2026
External Links
MENU
0
522 - Efficacy and safety of abrocitinib in combination with topical therapy in adolescents from China with moderate-to-severe atopic dermatitis: A post hoc analysis of the JADE TEEN phase 3 trial
Article 2024 EN
Abstract Background Atopic dermatitis (AD) has a reported prevalence of 3% in adolescents aged 13-14 years in China. However, studies evaluating the efficacy and safety of Janus kinase 1-selective inhibitors in AD in patients from China are limited. Abrocitinib is an oral, once-daily, Janus kinase 1–selective inhibitor approved for the treatment of moderate-to-severe AD in adults and adolescents i…
0
Citations
0
References
9
Authors
0.00
FWCI
Topics
Keywords
UN Sustainable Development Goals
1 SDGsAuthors & Affiliations
9 authors| # | Author | Institutions | ORCID |
|---|---|---|---|
| 1 | Zhirong Yao | Shanghai Jiao Tong University (CN) XinHua Hospital (CN) | |
| 2 | Aie Xu | Third People's Hospital of Han… (CN) | |
| 3 | Li He | First Affiliated Hospital of K… (CN) | |
| 4 | Yangfeng Ding | Tongji University (CN) Shanghai Skin Disease Hospital (CN) | |
| 5 | Guohong Hu | — | |
| 6 | Shefali Vyas | Pfizer (United States) (US) | — |
| 7 | Bo Wang | Pfizer (China) (CN) | |
| 8 | Xin Luo | Pfizer (China) (CN) | — |
| 9 | Shiqi Li | Pfizer (China) (CN) |
Related Works
10Data: OpenAlex